Ann: Opthea Completes Placement & Institutional Entitlement Offer, page-39

I like Opthea but as I posted back in 2022 (so no I'm not new here), I didn't see the point in holding it until they were much closer to their phase 3 readout. Should be obvious why since these things are by default a cash oven, and most investors get bored waiting. As for healthcare/biotech I have owned and still like/keep an eye on AVH, NAN, OPT and follow a bunch of others that look interesting. My post above doesn't bag the company or holders, just points out why it's hardly surprising that the underwriter of a massive cap raise quickly came out with an uber-bullish note. But you go with whatever narrative makes you feel good